Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

INTRODUCTION: Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which included a low percentage of underweight patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Bravo Villa, Verónica, Romero, Job, Rojas‐Zaldivar, Eunice, Cervantes, Martha, Villa‐Márquez, María del Rosario, Baz, Patricia, Cesarman‐Maus, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles ‐ Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035794/
https://www.ncbi.nlm.nih.gov/pubmed/33870027
http://dx.doi.org/10.1002/rth2.12492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035794/
https://www.ncbi.nlm.nih.gov/pubmed/33870027
http://dx.doi.org/10.1002/rth2.12492

Ejemplares similares